NephroGenex soars on cardiac safety data
This article was originally published in Scrip
US firm NephroGenex, which conducted its initial public offering early this year, saw its share price close up almost 300% at $13.35 on 31 December on news that its sole drug candidate, Pyridorin, was found to be safe in a cardiac safety study.
You may also be interested in...
Once-prosperous biotechs are now seeking strategic alternatives including the selling off of all of their assets now that they've failed to acquire the funds they need to move forward.
The UK's main reimbursement bodies made a series of decisions this week that were broadly favorable and largely focused on oncology medicines.
While troubled Valeant was divesting iNova to private equity investors, Novartis announced a pair of oncology-focused deals, out-licensing a brain cancer drug to Midatech and partnering with IBM Watson Health to optimize breast cancer treatment.